Proactive Investors - Run By Investors For Investors

Growth 'guaranteed' for a well funded Volition Rx

Cameron Reynolds, CEO of Volition Rx, the NYSE-listed company, brings Proactive Investors London an end of quarter catch up with newsflows in three key areas. First there's more news on their new routine blood test to screen for colorectal and prostate cancers which has reduced the need for more invasive colonoscopies and biopsies. Secondly, there's an update on the potential for further revenue streams for Volition once discovery grade assets convert to product grade opportunities. And lastly, how Volition continues to push into veterinary medicine while both well funded and keeping costs down.

 
View full VNRX profile View Profile

VolitionRx Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use